959972-34-0

Upstream product

• 1174709-11-5 C₆H₃IN₂O 
• 1174709-11-5 4-hydroxy-5-iodopyridine-3-carbonitrile 

Downstream Products

• 960041-28-5 4-[(2-chloro-5-hydroxyphenyl)amino]-5-iodonicotinonitrile 
• 1160923-88-5 4-chloro-5-[(E)-2-phenylvinyl]nicotinonitrile 
• 1160923-92-1 4-chloro-5-vinylnicotinonitrile 

Relevant academic research and scientific papers

Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCθ inhibitors

The key intermediate, 4-chloro-5-iodo-3-pyridinecarbonitrile, allowed for ready optimization of the PKCθ inhibitory activity of a series of 3-pyridinecarbonitriles. Analog 13b with a 4-methylindol-5-ylamino group at C-4 and a 4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl group at C-5 had an IC50 value of 7.4 nM for the inhibition of PKCθ.

5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS

Described herein are compounds of formula I: wherein G is and pharmaceutically acceptable salts thereof, wherein J, X, R1, R2, R11, R12' and p are as defined herein. Also provided herein are methods of making the compounds of formula I, and methods of using these compounds for inhibiting or treating a pathological condition or disorder linked to or mediated by a protein kinase in a mammal.

Substituted Cyanopyridines as protein kinase inhibitors

The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R1, R2, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.